The messenger's great message for vaccination

Expert Review of Vaccines

Volumn 14, Issue 2, 2014, Pages 153-156

  Pascolo, Steve ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

allergies; cancer; infections; messenger RNA; vaccine

Indexed keywords

MESSENGER RNA; RNA; CANCER VACCINE; DNA VACCINE;

ACIDITY; ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ADVANCED CANCER; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; CANCER IMMUNIZATION; CYTOTOXIC T LYMPHOCYTE; DESENSITIZATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; ENZYME ACTIVITY; GENE THERAPY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; IN VITRO STUDY; NONHUMAN; PH; PRIORITY JOURNAL; REVIEW; RNA ANALYSIS; RNA STABILITY; RNA VECTOR; VACCINATION; VIRAL GENE DELIVERY SYSTEM; GENE VECTOR; IMMUNOLOGY; NEOPLASMS;

CANCER VACCINES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; RNA, MESSENGER; VACCINATION; VACCINES, DNA;

EID: 84921384147     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2015.1000871     Document Type: Review

References (27)

1. Parvanova I, Rettig L, Knuth A, Pascolo S. The form of NY-ESO-1 antigen has an impact on the clinical efficacy of anti-Tumor vaccination. Vaccine 2011;29(22):3832-6
2. Sahin U, Kariko K. Tureci O. mRNA-based therapeutics - developing a new class of drugs. Nature reviews Drug discovery 2014; 13(10):759-80
3. Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science 1990;247(4949 Pt 1):1465-8
4. Conry RM, LoBuglio AF, Wright M, et al. Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res 1995;55(7):1397-400
5. Martinon F, Krishnan S, Lenzen G, et al. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur J Immunol 1993;23(7): 1719-22
6. Qiu P, Ziegelhoffer P, Sun J, Yang NS. Gene gun delivery of mRNA in situ results in efficient transgene expression and genetic immunization. Gene Ther 1996;3(3):262-8
7. Jirikowski GF, Sanna PP, Maciejewski-Lenoir D, Bloom FE. Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA. Science 1992;255(5047):996-8
8. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996; 184(2):465-72
9. Kreiter S, Selmi A, Diken M, et al. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res 2010;70(22): 9031-40
10. Zhou X, Berglund P, Rhodes G, et al. Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine 1994;12(16): 1510-14
11. Hoerr I, Obst R, Rammensee HG, Jung G. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol 2000;30(1):1-7
12. CureVac GmbH. Available from: www. curevac.com
13. Pascolo S. Vaccination with messenger RNA. Methods Mol Med 2006;127:23-40
14. Pascolo S. Vaccination with messenger RNA (mRNA). Handb Exp Pharmacol 2008(183):221-35
15. Pascolo S. Messenger RNA-based vaccines. Expert Opin Biol Ther 2004;4(8):1285-94
16. Probst J, Weide B, Scheel B, et al. Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent. Gene Ther 2007;14(15):1175-80
17. Kranz L, Fritz D, Haas H, et al. Characterization of the IFNa response upon systemic administration of targeted mRNA vaccine delivery. CIMT meeting abstract book. 2014
18. Steitz J, Britten CM, Wolfel T, Tuting T. Effective induction of anti-melanoma immunity following genetic vaccination with synthetic mRNA coding for the fusion protein EGFP.TRP2. Cancer Immunol Immunother 2006;55(3):246-53
19. Kuhn AN, Diken M, Kreiter S, et al. Determinants of intracellular RNA pharmacokinetics: implications for RNA-based immunotherapeutics. RNA Biol 2011;8(1):35-43
20. Carralot JP, Probst J, Hoerr I, et al. Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines. Cell Mol Life Sci 2004; 61(18):2418-24
21. Fotin-Mleczek M, Duchardt KM, Lorenz C, et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother 2011;34(1):1-15
22. Fotin-Mleczek M, Zanzinger K, Heidenreich R, et al. mRNA-based vaccines synergize with radiation therapy to eradicate established tumors. Radiat Oncol 2014;9:180
23. Ivac mutanome Phase I Clinical Trial. Available from: https://clinicaltrials.gov/ct2/show/NCT02035956
24. Van Lint S, Goyvaerts C, Maenhout S, et al. Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res 2012;72(7):1661-71
25. Martinez-Gomez JM, Johansen P, Erdmann I, et al. Intralymphatic injections as a new administration route for allergen-specific immunotherapy. Int Arch Allergy Immunol 2009;150(1):59-65
26. Roesler E, Weiss R, Weinberger EE, et al. Immunize and disappear-safety-optimized mRNA vaccination with a panel of 29 allergens. J Allergy Clin Immunol 2009; 124(5):1070-7.e1-11
27. Weiss R, Scheiblhofer S, Roesler E, et al. mRNA vaccination as a safe approach for specific protection from type I allergy. Expert Rev Vaccines 2012;11(1):55-67